Product Details
Synonyms
uPAR, PLAUR, CD87, MO3
Source
Human uPAR (115-305) Protein, His Tag (UPR-H52H7) is expressed from human 293 cells (HEK293). It contains AA Leu 115 - Gly 305 (Accession # Q03405-1).
Predicted N-terminus: Leu 115
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23 kDa. The protein migrates as 30-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human uPAR (115-305) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS

The purity of Human uPAR (115-305) Protein, His Tag (Cat. No. UPR-H52H7) is more than 90% and the molecular weight of this protein is around 25-40 kDa verified by SEC-MALS.
Report
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Urokinase plasminogen activator surface receptor
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
7 Details
- Highest Development Stage:
Phase 3 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















